ClinicalTrials.gg
CompletedNCT03570697Updated May 3, 2022Results posted

Imaging of Coronary Plaques in Participants Treated With Evolocumab

A Phase 3 interventional study of Evolocumab and Placebo in Coronary Artery Disease (CAD), sponsored by Amgen. Completed at 33 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-03.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 302 studies in Coronary Artery Disease with a site in Italy — 48 open to participants now, 71 under way, 7 of them phase 3. Coronary Artery Disease · Italy.

Enrollment
115th of 189
164 · median 290
Started
2018
with 13 others
Phase 3
37 of 302
3 open now
Registered
182nd of 302
by date

Among the 302 studies in Coronary Artery Disease with a site in Italy, this one is the 115th largest by enrollment of the 189 interventional ones that give a count, is one of 14 that started in 2018, is one of 37 in phase 3, and was the 182nd registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

48 of the 302 studies in Coronary Artery Disease with a site in Italy are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 302 studies in Coronary Artery Disease with a site in Italy, or all of them as a file.
02

Study summary

To evaluate the effect of evolocumab on fibrous cap thickness (FCT) in participants with non-ST-elevation acute coronary syndrome (NSTE-ACS) who are taking maximally tolerated statin therapy.

Read the detailed description

This study seeks to identify morphologic changes, such as increase in FCT in atherosclerotic plaques associated with treatment with evolocumab and maximally tolerated statin therapy with or without additional lipid-modifying medication in patients presenting with NSTE-ACS using optical coherence tomography (OCT; primary, secondary, and exploratory endpoints).

03

Conditions studied

  • Coronary Artery Disease (CAD)

Keywords

  • Optical coherence tomography (OCT)
  • Intravascular ultrasound (IVUS)
  • Coronary angiography
  • Coronary artery disease
  • Cardiovascular events
  • Coronary atherosclerotic plaques
  • Lipid-lowering therapy
  • Statin
  • Maximally tolerated statin therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provided prior to initiation of any study-specific activities/procedures.
  • Age greater than or equal to 18 years at screening
  • Clinical indication for coronary angiography during admission due to NSTE-ACS with interventional treatment of culprit plaque
  • An eligible low-density lipoprotein cholesterol (LDL-C) level via local lab assessment based on statin use at screening

No statin use: greater than or equal to 130 mg/dL Low- or moderate-intensity statin use greater than or equal to 80 mg/dL High-intensity statin use greater than or equal to 60 mg/dL

  • On maximally tolerated statin therapy in accordance with standard of care per local guidelines prior to randomization.
  • Tolerates placebo run-in injection at screening
  • Meets all the following criteria at the qualifying coronary angiogram:

Angiographic evidence of coronary artery disease (CAD) with greater than or equal to 20% reduction of lumen diameter by angiographic visual estimation, in addition to the culprit plaque.

Left main coronary artery must not have a greater than 50% reduction in lumen diameter by visual angiographic estimation.

Targeted vessel:

May not be the culprit vessel for the current or a previous myocardial infarction (MI).

Has not undergone prior percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), and may not be a bypass graft.

May not be a candidate for PCI or CABG currently or over the next 12 months, in the opinion of the investigator.

Must be accessible by the optical coherence tomography (OCT) catheter.

Targeted segment:

Must have up to 50% but not greater than 50% reduction in lumen diameter by visual angiographic estimation and must be at least 40 mm in length.

Must contain at least 1 image with a fibrous cap thickness (FCT) of less than or equal to 120 μm and at least 1 image with a lipid arc of greater than 90° as determined by the imaging core laboratory Distal plaques of up to 50% stenosis by visual angiographic estimation are permitted, provided that such stenosis is not a target for PCI or CABG.

Exclusion criteria

Exclusion Criteria:

  • ST-segment elevation myocardial infarction (STEMI) or left bundle branch block (LBBB).
  • Acute coronary syndromes (ACS) likely to be caused by a non-atherosclerotic process, in the opinion of the investigator (ie, type 2 myocardial infarction, which is characterized by an imbalance between myocardial oxygen demand and supply).
  • heart disease which in the opinion of the investigator is likely to require coronary bypass surgery, PCI (does not apply to PCI of non-STEMI (NSTEMI) during initial screening angiogram), surgical or percutaneous valve repair and/or replacement during the course of the study.
  • Any cardiac surgery within 6 weeks prior to screening.
  • Triglycerides greater than or equal to 400 mg/dL (4.5 mmol/L) at screening.
  • Moderate to severe renal dysfunction, defined as an estimated (eGFR) less than 30 mL/min/1.73m\^2 at screening.
  • except non-melanoma skin cancers, cervical, or breast ductal carcinoma in situ within the last 5 years.
  • Intolerant to statins as determined by principal investigator.
  • Previously received or receiving evolocumab or any other therapy to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9).
  • Previously received a cholesterol ester transfer protein (CETP) inhibitor (ie, anacetrapib, dalcetrapib, evacetrapib), mipomersen, lomitapide, or has undergone LDL-apheresis in the last 12 months prior to LDL-C screening.
  • Currently receiving treatment in another device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
  • Baseline OCT does not meet OCT imaging criteria as determined by the imagine core laboratory technical standards.
  • Female subject is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 15 weeks after the last dose of investigational product. (Females of should only be included in the study after a confirmed menstrual period and a negative highly sensitive urine or serum pregnancy test.)
  • Female subjects of childbearing potential unwilling to use 1 acceptable method of effective during treatment and for an additional 15 weeks after the last dose of investigational product.
  • Female subject who has not used an acceptable method(s) of birth control for at least 1 month prior to screening, unless the female subject is sterilized or .
  • Known sensitivity to any of the products or components (eg, carboxymethylcellulose) to be administered during dosing.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
164 participants (actual)

Study arms

  • Experimental
    Evolocumab

    Participants receive evolocumab subcutaneous injection once every month (QM) for 48 weeks. As prescribed and provided by the investigator, participants will be treated with maximally tolerated statin therapy, not expected to change for the duration of the study participation.

    Drug: Evolocumab · Drug: Statin therapy

  • Placebo comparator
    Placebo

    Participants receive placebo subcutaneous injection QM for 48 weeks. As prescribed and provided by the Investigator, participants will be treated with maximally tolerated statin therapy, not expected to change for the duration of the study participation.

    Drug: Placebo · Drug: Statin therapy

Interventions

  • Participants will receive evolocumab (AMG 145) subcutaneous monthly.

    Also known as: Repatha, AMG 145, EvoMab

  • DrugPlacebo

    Participants will receive matching placebo subcutaneous monthly.

  • high-intensity statin treatment with atorvastatin ≥ 40 mg daily or equivalent as background therapy Investigators will up-titrate statin therapy to the maximally tolerated dose, in accordance with local guidelines, prior to randomization.

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Minimum FCT

    Absolute change from baseline in minimum FCT in a matched segment of artery as determined by OCT. Minimum FCT for a participant is defined as the minimum of all minimum FCT measurements within each individual frame across all frames of that participant. Higher value of FCT indicates a better situation.

    Time frame: Baseline, week 50

Secondary outcomes

  1. Percent Change From Baseline in Minimum FCT

    Percent change from baseline in minimum FCT in a matched segment of artery as determined by OCT. Minimum FCT for a participant is defined as the minimum of all minimum FCT measurements within each individual frame across all frames of that participant. Higher value of FCT indicates a better situation.

    Time frame: Baseline, week 50

  2. Absolute Change From Baseline in Mean Minimum FCT

    Absolute change from baseline in mean minimum FCT for all images assessed in an individual participant as determined by OCT. Minimum FCT for a participant is defined as the minimum of all minimum FCT measurements within each individual frame across all frames of that participant. Higher value of FCT indicates a better situation.

    Time frame: Baseline, week 50

  3. Absolute Change From Baseline in the Maximum Lipid Arc

    Absolute change from baseline in the maximum lipid arc in a matched segment of artery as determined by OCT. Lower value of lipid arc indicates a better situation.

    Time frame: Baseline, week 50

  4. Absolute Change From Baseline in Minimum FCT in Lipid Rich Plaques

    Absolute change from baseline in minimum FCT in lipid rich plaques as determined by OCT. Lipid rich plaques are defined as minimum FCT less than 120 μm and lipid arc greater than 90° in at least 3 consecutive images as determined by OCT. Higher value of FCT indicates a better situation

    Time frame: Baseline, week 50

  5. Absolute Change From Baseline in Maximum Lipid Arc in Lipid Rich Plaques

    Absolute change from baseline in maximum lipid arc in lipid rich plaques. Lipid rich plaques are defined as minimum FCT less than 120 μm and lipid arc greater than 90° in at least 3 consecutive images as determined by OCT. Lower value of lipid arc indicates a better situation.

    Time frame: Baseline, week 50

  6. Absolute Change From Baseline in Lipid Core Length in Lipid Rich Plaques

    Absolute change from baseline in lipid core length in lipid rich plaques. Lipid rich plaques are defined as minimum FCT less than 120 μm and lipid arc greater than 90° in at least 3 consecutive images as determined by OCT. Lower value of lipid core length indicates a better situation.

    Time frame: Baseline, week 50

07

Results

Posted Nov 24, 2021

Participant flow

Participants were enrolled at 23 research centers in Australia (2), Czech Republic (2), Germany (2), Hungary (4), Italy (6), and the Netherlands (7), from November 2018 to December 2019.

Participant flow — Overall Study
MilestonePlaceboEvolocumab
Started8282
Received at least 1 dose of study drug8180
Completed7679
Not completed63
Withdrew: Lost to follow-up01
Withdrew: Death20
Withdrew: Withdrawal by subject42

Outcome measures

PrimaryAbsolute Change From Baseline in Minimum FCT

Absolute change from baseline in minimum FCT in a matched segment of artery as determined by OCT. Minimum FCT for a participant is defined as the minimum of all minimum FCT measurements within each individual frame across all frames of that participant. Higher value of FCT indicates a better situation.

Time frame:
Baseline, week 50
Reported as:
Least squares mean · µm
Absolute Change From Baseline in Minimum FCT
µmPlaceboEvolocumab
Absolute Change From Baseline in Minimum FCT21.5 ± 5.242.7 ± 5.1
Statistical analysis
  • Placebo vs Evolocumab · ANCOVA · p = 0.015 · Treatment difference: 21.2 · 95% CI 4.7 to 37.7
SecondaryPercent Change From Baseline in Minimum FCT

Percent change from baseline in minimum FCT in a matched segment of artery as determined by OCT. Minimum FCT for a participant is defined as the minimum of all minimum FCT measurements within each individual frame across all frames of that participant. Higher value of FCT indicates a better situation.

Time frame:
Baseline, week 50
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Minimum FCT
percent changePlaceboEvolocumab
Percent Change From Baseline in Minimum FCT44.30 ± 11.7681.76 ± 10.94
Statistical analysis
  • Placebo vs Evolocumab · ANCOVA · p = 0.041 · Treatment difference: 37.47 · 95% CI 1.63 to 73.31
SecondaryAbsolute Change From Baseline in Mean Minimum FCT

Absolute change from baseline in mean minimum FCT for all images assessed in an individual participant as determined by OCT. Minimum FCT for a participant is defined as the minimum of all minimum FCT measurements within each individual frame across all frames of that participant. Higher value of FCT indicates a better situation.

Time frame:
Baseline, week 50
Reported as:
Least squares mean · µm
Absolute Change From Baseline in Mean Minimum FCT
µmPlaceboEvolocumab
Absolute Change From Baseline in Mean Minimum FCT29.78 ± 6.8862.29 ± 5.95
Statistical analysis
  • Placebo vs Evolocumab · ANCOVA · p = 0.003 · Treatment difference: 32.51 · 95% CI 12.67 to 52.35
SecondaryAbsolute Change From Baseline in the Maximum Lipid Arc

Absolute change from baseline in the maximum lipid arc in a matched segment of artery as determined by OCT. Lower value of lipid arc indicates a better situation.

Time frame:
Baseline, week 50
Reported as:
Least squares mean · degrees
Absolute Change From Baseline in the Maximum Lipid Arc
degreesPlaceboEvolocumab
Absolute Change From Baseline in the Maximum Lipid Arc-31.4 ± 9.0-57.5 ± 7.4
Statistical analysis
  • Placebo vs Evolocumab · ANCOVA · p = 0.032 · Treatment difference: -26.0 · 95% CI -49.6 to -2.4
SecondaryAbsolute Change From Baseline in Minimum FCT in Lipid Rich Plaques

Absolute change from baseline in minimum FCT in lipid rich plaques as determined by OCT. Lipid rich plaques are defined as minimum FCT less than 120 μm and lipid arc greater than 90° in at least 3 consecutive images as determined by OCT. Higher value of FCT indicates a better situation

Time frame:
Baseline, week 50
Reported as:
Least squares mean · μm
Absolute Change From Baseline in Minimum FCT in Lipid Rich Plaques
μmPlaceboEvolocumab
Absolute Change From Baseline in Minimum FCT in Lipid Rich Plaques24.6 ± 5.540.6 ± 5.5
Statistical analysis
  • Placebo vs Evolocumab · ANCOVA · p = 0.036 · Treatment difference: 16.0 · 95% CI 1.1 to 31.0
SecondaryAbsolute Change From Baseline in Maximum Lipid Arc in Lipid Rich Plaques

Absolute change from baseline in maximum lipid arc in lipid rich plaques. Lipid rich plaques are defined as minimum FCT less than 120 μm and lipid arc greater than 90° in at least 3 consecutive images as determined by OCT. Lower value of lipid arc indicates a better situation.

Time frame:
Baseline, week 50
Reported as:
Least squares mean · degrees
Absolute Change From Baseline in Maximum Lipid Arc in Lipid Rich Plaques
degreesPlaceboEvolocumab
Absolute Change From Baseline in Maximum Lipid Arc in Lipid Rich Plaques-31.9 ± 8.1-61.9 ± 7.9
Statistical analysis
  • Placebo vs Evolocumab · ANCOVA · p = 0.005 · Treatment difference: -30.0 · 95% CI -50.5 to -9.5
SecondaryAbsolute Change From Baseline in Lipid Core Length in Lipid Rich Plaques

Absolute change from baseline in lipid core length in lipid rich plaques. Lipid rich plaques are defined as minimum FCT less than 120 μm and lipid arc greater than 90° in at least 3 consecutive images as determined by OCT. Lower value of lipid core length indicates a better situation.

Time frame:
Baseline, week 50
Reported as:
Least squares mean · mm
Absolute Change From Baseline in Lipid Core Length in Lipid Rich Plaques
mmPlaceboEvolocumab
Absolute Change From Baseline in Lipid Core Length in Lipid Rich Plaques-3.33 ± 0.64-5.76 ± 0.61
Statistical analysis
  • Placebo vs Evolocumab · ANCOVA · p = 0.003 · Treatment difference: -2.43 · 95% CI -4.04 to -0.82

Adverse events

Collected over All cause mortality reporting period is from the 1st dose of investigational product (IP) up to the end of study (EOS) date (Week 52). Adverse event (AE) reporting period is from the 1st dose of IP up to and including 30 days after the last dose of IP date or the EOS date (Week 52) whichever is earlier.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo2/82 (2.4%)16/81 (19.8%)30/81 (37%)
Evolocumab0/82 (0%)13/80 (16.3%)31/80 (38.8%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventPlaceboEvolocumab
Acute myocardial infarctionCardiac disorders3/810/80
Normocytic anaemiaBlood and lymphatic system disorders0/811/80
Acute coronary syndromeCardiac disorders1/811/80
Angina pectorisCardiac disorders0/811/80
Coronary artery diseaseCardiac disorders0/811/80
Coronary artery stenosisCardiac disorders1/811/80
Ventricular fibrillationCardiac disorders0/811/80
Colitis ulcerativeGastrointestinal disorders0/811/80
Gastrointestinal angiodysplasiaGastrointestinal disorders0/811/80
Enterococcal infectionInfections and infestations0/811/80
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPlaceboEvolocumab
Angina pectorisCardiac disorders7/814/80
HypertensionVascular disorders5/816/80
MyalgiaMusculoskeletal and connective tissue disorders6/815/80
DiarrhoeaGastrointestinal disorders4/813/80
FatigueGeneral disorders2/813/80
EpistaxisRespiratory, thoracic and mediastinal disorders0/813/80
HypotensionVascular disorders1/813/80
Muscle spasmsMusculoskeletal and connective tissue disorders3/810/80
CoughRespiratory, thoracic and mediastinal disorders3/812/80
BradycardiaCardiac disorders0/812/80

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboEvolocumabTotal
Mean60.4 ± 9.461.1 ± 10.060.8 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEvolocumabTotal
Female262046
Male5662118
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboEvolocumabTotal
Hispanic or Latino145
Not Hispanic or Latino8178159
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboEvolocumabTotal
Asian112
White8079159
Other, Not Specified123
Stratification Factor: Statin Use at Screening
Stratification Factor: Statin Use at Screening(Participants)PlaceboEvolocumabTotal
> 4 weeks of statin use201939
≤ 4 weeks of statin use6263125
Minimum Fibrous Cap Thickness (FCT)
Minimum Fibrous Cap Thickness (FCT)(µm)PlaceboEvolocumabTotal
Mean54.6 ± 15.156.6 ± 17.855.6 ± 16.5
08

Study locations

33 sites
  • University of California at Los Angeles
    Los Angeles, California 90095, United States
  • Medstar Heart and Vascular Institute
    Washington, District of Columbia 20010, United States
  • Midwest Cardiovascular Research And Education Foundation
    Elkhart, Indiana 46514, United States
  • Saint Louis University Hospital
    Saint Louis, Missouri 63110, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Royal North Shore Hospital
    St Leonards, New South Wales 2065, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • The Northern Hospital
    Epping, Victoria 3076, Australia
  • Fakultni nemocnice Brno
    Brno, 625 00, Czechia
  • Fakultni nemocnice Hradec Kralove
    Hradec Kralove, 500 05, Czechia
  • Charite Universitätsmedizin Berlin Campus Benjamin Franklin
    Berlin, 12203, Germany
  • Universitäres Herzzentrum Hamburg GmbH
    Hamburg, 20246, Germany
  • Deutsches Herzzentrum München des Freistaates Bayern
    München, 80636, Germany
  • Allami Szivkorhaz Balatonfured
    Balatonfured, 8230, Hungary
  • Semmelweis Egyetem
    Budapest, 1122, Hungary
  • Magyar Honvedseg Egeszsegugyi Kozpont
    Budapest, 1134, Hungary
  • Pecsi Tudomanyegyetem Klinikai Kozpont
    Pecs, 7624, Hungary
  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
    Bergamo, 24127, Italy
  • Azienda Ospedaliera Santa Croce e Carle
    Cuneo, 12100, Italy
  • Azienda Ospedaliera Universitaria Careggi
    Firenze, 50134, Italy
  • IRCCS Centro Cardiologico Monzino
    Milano, 20138, Italy
  • Azienda Ospedaliera Universitaria Federico II
    Napoli, 80131, Italy
  • Azienda Ospedaliera San Giovanni Addolorata
    Roma, 00184, Italy
  • IRCCS Istituto Clinico Humanitas
    Rozzano MI, 20089, Italy
  • Noordwest Ziekenhuisgroep
    Alkmaar, 1815 JD, Netherlands
  • Vrjie Universiteit Medisch Centrum
    Amsterdam, 1081 HV, Netherlands
  • Onze Lieve Vrouwe Gasthuis
    Amsterdam, 1091 AC, Netherlands
  • Radboud Universitair Medisch Centrum
    Nijmegen, 6525 GA, Netherlands
  • Canisius-Wilhelmina Ziekenhuis
    Nijmegen, 6532 SZ, Netherlands
  • Elisabeth-TweeSteden Ziekenhuis
    Tilburg, 5042 AD, Netherlands
  • Isala Klinieken
    Zwolle, 8025 AB, Netherlands
09

References and documents

Publications

  • Nicholls SJ, Nissen SE, Prati F, Windecker S, Kataoka Y, Puri R, Hucko T, Kassahun H, Liao J, Somaratne R, Butters J, Di Giovanni G, Jones S, Psaltis PJ. Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study. Cardiovasc Diagn Ther. 2021 Feb;11(1):120-129. doi: 10.21037/cdt-20-684. PubMed 33708484 ↗
  • Pharmacoeconomic Review Report: Icosapent Ethyl (Vascepa): (HLS Therapeutics Inc.): Indication: Prevention of cardiovascular events in statin-treated patients [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Aug. Available from http://www.ncbi.nlm.nih.gov/books/NBK566010/ PubMed 33355725 ↗
  • Nicholls SJ, Kataoka Y, Nissen SE, Prati F, Windecker S, Puri R, Hucko T, Aradi D, Herrman JR, Hermanides RS, Wang B, Wang H, Butters J, Di Giovanni G, Jones S, Pompili G, Psaltis PJ. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC Cardiovasc Imaging. 2022 Jul;15(7):1308-1321. doi: 10.1016/j.jcmg.2022.03.002. Epub 2022 Mar 16. PubMed 35431172 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Dec 2020, 24 months.

Results were first posted in Nov 2021, 11 months after primary completion.

Of 29 industry-sponsored phase 3 interventional studies under Coronary Artery Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's 24 months is below that.

Counting every sponsor, half of 61 studies reached it within 47 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2018
First posted
Jun 27, 2018
StartActual
Nov 19, 2018
Primary completionActual
Dec 18, 2020
CompletionActual
Jan 21, 2021
Results first posted
Nov 24, 2021
Last update
May 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03570697
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 27, 2018
Start date
Nov 19, 2018
Primary completion
Dec 18, 2020
Completion
Jan 21, 2021
Results posted
Nov 24, 2021
Last update
May 3, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evolocumab

Start the discussion